Xencor (NASDAQ:XNCR) Downgraded to “Sell” Rating by StockNews.com

StockNews.com downgraded shares of Xencor (NASDAQ:XNCR) from a hold rating to a sell rating in a research note published on Friday.

Several other brokerages have also weighed in on XNCR. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company dropped their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.38.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $12.76 on Friday. The stock has a fifty day simple moving average of $17.36 and a two-hundred day simple moving average of $20.42. Xencor has a 1-year low of $12.69 and a 1-year high of $27.24. The firm has a market cap of $899.10 million, a price-to-earnings ratio of -3.99 and a beta of 0.74. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Analysts anticipate that Xencor will post -3.68 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 508 shares in the last quarter. KBC Group NV raised its position in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 949 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares in the last quarter. Finally, Summit Investment Advisors Inc. raised its position in shares of Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 1,282 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.